Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$54.52
1.512.85%
At close: -
$54.25
-0.27-0.50%
After Hours: 4:22 PM EDT
Comments
Loading...
Protagonist Therapeutics Analyst Ratings and Price Targets | NASDAQ:PTGX | Benzinga
Protagonist Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Protagonist Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
BMO Capital
HC Wainwright & Co.
Citizens Capital Markets
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Protagonist Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/11/2025 | Buy Now | — | Truist Securities | Srikripa Devarakonda | $60 → $76 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | — | BMO Capital | Etzer Darout | $62 → $72 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $54 → $80 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | — | Citizens Capital Markets | Jonathan Wolleben | $61 → $61 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/10/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | — | JP Morgan | Brian Cheng | $53 → $57 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | — | Goldman Sachs | — | $43 → $38 | Maintains | Neutral | Get Alert |
| 02/24/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $54 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | JMP Securities | Jonathan Wolleben | $58 → $58 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/07/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | — | JP Morgan | Brian Cheng | $51 → $53 | Maintains | Overweight | Get Alert |
| 12/10/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | — | BMO Capital | Etzer Darout | → $62 | Initiates | → Outperform | Get Alert |
| 11/22/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | — | Wedbush | Yun Zhong | → $58 | Initiates | → Outperform | Get Alert |
| 09/24/2024 | Buy Now | — | TD Cowen | Tara Bancroft | → $65 | Initiates | → Buy | Get Alert |
| 09/12/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $40 → $50 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda | → $60 | Initiates | → Buy | Get Alert |
| 08/07/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben | $45 → $43 | Maintains | Market Outperform | Get Alert |
| 08/07/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $38 → $40 | Maintains | Buy | Get Alert |
| 07/25/2024 | Buy Now | — | JP Morgan | Brian Cheng | $39 → $48 | Maintains | Overweight | Get Alert |
| 07/24/2024 | Buy Now | — | BTIG | Julian Harrison | $41 → $51 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben | $45 → $45 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/14/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben | $42 → $45 | Maintains | Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben | $42 → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | — | JP Morgan | Brian Cheng | $34 → $37 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben | $35 → $37 | Maintains | Market Outperform | Get Alert |
| 10/30/2023 | Buy Now | — | Capital One | Tim Chiang | — | Initiates | → Overweight | Get Alert |
| 10/10/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | Buy Now | — | JP Morgan | Brian Cheng | $36 → $34 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben | $28 → $35 | Maintains | Market Outperform | Get Alert |
| 07/03/2023 | Buy Now | — | Piper Sandler | Yasmeen Rahimi | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 07/03/2023 | Buy Now | — | BTIG | Julian Harrison | → $41 | Reiterates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/27/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | → $38 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben | $31 → $28 | Maintains | Market Outperform | Get Alert |
| 03/16/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $33 → $38 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben | $21 → $31 | Maintains | Market Outperform | Get Alert |
| 11/10/2022 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | $50 → $33 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | — | JMP Securities | Jonathan Wolleben | → $21 | Reinstates | → Market Outperform | Get Alert |
| 05/18/2022 | Buy Now | — | Piper Sandler | Yasmeen Rahimi | $60 → $35 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | — | SVB Leerink | Joseph Schwartz | $50 → $30 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by Truist Securities on March 11, 2025. The analyst firm set a price target for $76.00 expecting PTGX to rise to within 12 months (a possible 40.09% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protagonist Therapeutics (PTGX)?
The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by Truist Securities, and Protagonist Therapeutics maintained their buy rating.
When was the last upgrade for Protagonist Therapeutics (PTGX)?
There is no last upgrade for Protagonist Therapeutics
When was the last downgrade for Protagonist Therapeutics (PTGX)?
There is no last downgrade for Protagonist Therapeutics.
When is the next analyst rating going to be posted or updated for Protagonist Therapeutics (PTGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.
Is the Analyst Rating Protagonist Therapeutics (PTGX) correct?
While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a maintained with a price target of $60.00 to $76.00. The current price Protagonist Therapeutics (PTGX) is trading at is $54.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.